JK
Jae-Weon Kim
Seoul National University Hospital, Seoul National University College of Medicine
Research areas: Medicine · Oncology · Ovarian cancer diagnosis and treatment · Endometrial and Cervical Cancer Treatments · Cervical Cancer and HPV Research
0000-0003-1835-9436
About
Gynecologic Oncologist
Employment
-
Seoul National University Hospital Professor1998 - Present
Education
-
Seoul National University College of Medicine MD, PhD
Projects & Funding
Projects & funding information is unavailable.
Publications (371)
- Effectiveness of first-line niraparib maintenance in Korean patients with advanced ovarian cancer: a multicenter retrospective cohort study Save
- Data from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Data S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Figure S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Figure S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Figure S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Table S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Table S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Table S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Supplementary Table S4 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor Save
- Evolving global governance in gynecologic oncology trials: toward trilateral academic collaboration Save
- Association of primary treatment modality and programmed death-ligand 1 expression with survival outcomes in locally advanced human papillomavirus–independent endocervical adenocarcinoma Save
- Reconnecting and advancing: East Asian collaboration in obstetrics and gynaecology after the 2025 Tokyo-Beijing-Seoul Joint Meeting Save
- Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework Save
- Is chemo-immunotherapy really beneficial for platinum-resistant ovarian cancer? Save
- Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE) Save
- Reconciling modest median progression-free survival and larger overall survival gains in platinum-resistant ovarian cancer Save
- Updated clinical practice guidelines for human papillomavirus vaccination: the Korean Society of Gynecologic Oncology recommendations Save
- Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Save